ROCKLAND, Mass.--(EON: Enhanced Online News)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is proud to announce that Lisa Costantino, Chief Financial Officer (CFO), has been appointed to the South Shore Hospital Board of Directors. Her term on the board began on Aug 1, 2013.
“Her professional expertise – coupled with her strong commitment to our charitable mission – will make her an asset to our governing body.”
“We are truly delighted that Lisa Costantino has joined our Board,” said Kenneth Kirkland, South Shore Hospital Board Chairman and Managing Partner of KAF Financial Group. “Her professional expertise – coupled with her strong commitment to our charitable mission – will make her an asset to our governing body.”
Costantino started with EMD Serono more than 30 years ago as an accounts payable clerk and held positions of increasing responsibility until being appointed as CFO in 2009.
In her role as CFO, Costantino’s responsibilities include the oversight and strategic direction-setting of the financial framework within the US organization. In addition, she is responsible for collaborating with a variety of global functions across the business.
She has been a key contributor to a number of important strategic initiatives for the company, including the acquisition of Serono by Merck KGaA, Darmstadt, Germany.
Costantino was recognized by the Boston Business Journal as its 2010 CFO of the Year, and was named to the PharmaVOICE 100 list of Most Inspiring People in 2012. Additionally, Costantino received the CEO Award from EMD Serono in 2003 and the President’s Award from EMD Serono in 2006.
Throughout her career, Costantino has been an active community member, working with organizations such as the National Multiple Sclerosis Society, Boys and Girls Club of America, Home for Little Wanderers, and Magical Moon Foundation among others. Costantino holds a bachelor of science in accounting from the University of Massachusetts, and an MBA from Suffolk University.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA
Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merckgroup.com.